Australian clinical experts have developed an interim “consensus advice” for prescribers of medicinal cannabis to patients with epilepsy.

Published in the British Journal of Clinical Pharmacology, the document provides an overview of the different cannabis medicines currently available for treating epilepsy in children and adults, with information on dose, drug interactions, toxicity, and type and frequency of symptom and seizure relief.

Senior author Professor Jennifer Martin

The work of a group of Australian paediatric and adult epilepsy specialists, clinical pharmacists, pharmacologists, and cannabis researchers, the advice will be updated as new evidence emerges and will provide the structure for a more definitive guideline in the future.

Senior author, University of Newcastle researcher and director of the Australian Centre for Cannabis Clinical and Research Excellence Professor Jennifer Martin said: “In the absence of a registration dossier, scientific experiments and case reports are helpful to provide some guidance to optimised dosing.

“However, as in this guidance, observational data obtained from clinical practice — which often includes information not included in scientific experiments or even early clinical trial data, such as treating patients with other co-morbidities, taking multiple medications, and patient diversity — can be very helpful to clinical practice.”

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...